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Abstract 23 
Dorzolamide 2%, timolol 0.5% and latanoprost 0.005% are widely used in the medical 24 
management of glaucoma in humans and pets. In this study, we wanted to evaluate the effect 25 
of these three molecules belonging to different hypotensive families on intraocular pressure 26 
(IOP) and anterior segment architecture in clinically healthy cats and compare these data with 27 
those obtained in a previous study under the same conditions in healthy dogs. In this prospective 28 
study 45 cats were included and divided into 3 homogeneous groups. For 7 days eye drops were 29 
instilled in the right eye (treated eye), dorzolamide 2% BID for the first group, timolol 0.5% 30 
BID for the second group and latanoprost 0.005% SID for the third group. The left (untreated) 31 
eye of all these cats constitute a control group useful for the statistical analysis of the data. On 32 
D0 and D7, the IOP was measured with Tonovet® and then, a high frequency ultrasound 33 
(ultrasound biomicroscopy UBM) was undertaken under general anesthesia. A biostatistical 34 
study of the 1440 data was then performed. Statistical test validated the use of the controlateral 35 
eye as a control, and the representativeness of a sample of 15 animals per group. At D7, the 36 
IOP of healthy cats treated with dorzolamide 2% BID decreased significantly whereas no 37 
variation was obtained with instillation of timolol 0.5% and latanoprost 0.005%. According to 38 
our protocol, these three hypotensive molecules do not significantly affect the architecture of 39 
the anterior segment of the clinically healthy feline eye as in dogs. 40 
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Introduction 48 
A common feature of all glaucoma in animals is the neurodegenerative disorder of retinal 49 
ganglion cells (RGCs) and their axons, an abnormal increase in intraocular pressure (IOP) 50 
represents a constant risk factor [Stiles, 2013]. The IOP is maintained at a relatively constant 51 
level and the rate of aqueous humor (AH) formation equals the outflow. Increase in IOP results 52 
from impairment of the aqueous humor outflow through the trabecular conventional pathway 53 
and/or through the uveoscleral pathway. It is estimated that glaucoma can affect about 1% of 54 
cats over the age of seven [Kroll et al., 2001] and most cases of feline glaucoma are secondary 55 
[Stiles, 2013]. 56 
Current therapy for feline glaucoma follows the same guidelines used in other species. Medical 57 
therapeutic option includes many topical hypotensive agents used in humans and dogs. Among 58 
hypotensive drugs, 3 families are commonly used: carbonic anhydrase inhibitors (such as 59 
dorzolamide), beta-blockers (such as timolol) and prostaglandin analogs (such as latanoprost). 60 
Dorzolamide reduces the active formation of HA by inhibiting the action of carbonic anhydrase, 61 
which is found abundantly in the ciliary body epithelial cells. Timolol as a beta-blocker, lowers 62 
aqueous humor flow by altering the adrenergic neuronal control of aqueous humor formation 63 
by blockade of the beta-receptors in the ciliary body processes, it may also inhibit active 64 
transport and ultrafiltration related to sodium transfer system. Latanoprost reduces IOP by 65 
increasing the uveoscleral outflow.  The remodeling of the extracellular matrix between the 66 
ciliary muscle fibers by local metalloproteases contributes to this pharmacological effect 67 
[Plummer et al., 2013]. 68 
In a recent study by Poinsard et al., 2018, these three hypotensive drugs lowered significantly 69 
IOP in dogs without modification of the biometry of the iridocorneal angle (ICA). This result 70 
is consistent with the hypotensive effect of dorzolamide and timolol on ciliary body epithelium 71 
but it is more surprising with latanoprost which increases the uveoscleral outflow of aqueous 72 
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humor, all the more so as a previous study shows that the biometry of the anterior segment and 73 
the ciliary cleft is modified two hours after the application of a drop of latanoprost 0,005% in 74 
dogs [Gelatt and Mackay, 2001]. 75 
The goal of this study was to compare the effect of these three hypotensive molecules on IOP 76 
and biometry of the anterior segment of healthy cats, as well as to compare these data with 77 
those obtained by Poinsard et al., 2018 in healthy dogs with the same protocol under the same 78 
conditions. To evaluate the biometry of the anterior segment, we used high-frequency 79 
immersion ultrasound with high definition (20-50µm) for structures up to 5mm deep 80 
[Leibmann, 1998], while being non-invasive, and for which most of the parameters of the 81 
anterior segment have already been objectified in healthy cats [Aubin, 2003]. 82 
 83 
Materials and Methods 84 
 85 
1. Inclusion criteria 86 
This prospective study with a control group was performed using 45 healthy cats without any 87 
current local or systemic treatment. These 45 cats belonged to staff or customers of the 88 
Lorrainevet veterinary clinic. All the dogs were included with the consent of their owners. A 89 
complete general and ophthalmic examination including slit-lamp biomicroscopy and indirect 90 
ophthalmoscopy without pupillary dilatation was performed, followed by an evaluation of IOP 91 
using a rebound tonometer (Tonovetâ, Icare, Vantaa, Finland). All animals with an 92 
ophthalmologic history or a difference greater than 2 mmHg IOP (on an average of three IOP 93 
measurements) on both eyes were excluded from the study. 94 
 95 
2. Experimental protocol 96 
Commenté [MOU1]: cats 
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Cats were divided into 3 homogeneous groups (weight, age, sex, race) of 15 cats (Table I). The 97 
study was done in two steps, spaced 7 days apart. The first step (D0) was performed in a 98 
mesopic environment, a complete general and ophthalmic examination, without dilation and 99 
without any instillation, was carried out between 10 am and 1 pm for each animal. IOP was an 100 
average of three measures on each eye. Ultrasound biomicroscopy (UBM) examination 101 
(Avisoâ, Quantel Medical, Cournon d'Auvergne, France) was then performed under isoflurane 102 
gas anesthesia after medetomidine premedication and ketamine induction. At the awakening of 103 
each animal, eye drops were instilled into the right eye. For group 1, one drop of dorzolamide 104 
2% (Trusopt 20mg / ml eye drops ND, MSD, Courbevoie, France) was instilled twice daily, at 105 
7am and 7pm, from D0 at 7pm until D7 at 7am. For group 2, one drop of 0.5% timolol 106 
(Timoptol 0.5% eye drops, MSD, Courbevoie, France) was instilled twice daily according to 107 
the same protocol as group 1. For group 3, one drop of latanoprost 0.005% (Xalatan 0.005% 108 
eye drops ND, Pfizer, Paris, France) was instilled once a day at 10pm in the fornix of the right 109 
eye for seven days, from D0 at 10 pm until D6 at 10 pm included. 110 
In the second step, on day 7, all animals were re-examined 12 hours after the last drop of 111 
latanoprost and 6 hours after the last drop of dorzolamide or timolol, with the same procedure 112 
under the same conditions as on D0. All examinations and UBM ultrasound were performed by 113 
the same operator on D0 and D7. 114 
3. UBM high frequency ocular ultrasound 115 
The ultrasound biomicroscopy for this study was a 50Mhz monotransducer with immersion 116 
probe with a geometric focalization and line scanning (UBM Avisoâ, Quantel Medical, 117 
Cournon d'Auvergne, France). The patient was positioned in dorsal recumbency with its head 118 
stabilized in a vacuum pillow. Two video sequences were recorded for each eye at D0 and D7. 119 
The first sequence was recorded by placing the probe both centrally and perpendicular to the 120 
corneal surface to determine the distance between the apex of the corneal endothelium and the 121 
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apex of the anterior capsule of the lens, at the 12 o'clock position. In the second sequence, the 122 
outflow pathways were evaluated in the dorsal quadrant with the probe placed perpendicular to 123 
the corneoscleral limbus at the 12 o'clock position. From each video sequence, one image was 124 
chosen for analysis (Figure 1). 125 
4. The anterior segment parameters 126 
Nine parameters were evaluated (Figure 2): (a) the ICA , (b) the width of the entrance of the 127 
ciliary cleft (CC), (c) the width of the mid-CC, (d) the length of CC, (e) the depth of the anterior 128 
chamber (AC), (f) the thickness of cornea at the corneoscleral limbus note, (g) the distance 129 
between Schwalbe’s line (the borderline between the cornea and sclera) and the anterior lens 130 
capsule according to Kawata and Hasegawa., 2013 and (h) the area of the ciliary cleft. These 131 
parameters were those described by Dulaurent et al., 2012 and used by Poinsard et al., 2018. 132 
The ICA (a) was the angle formed by the base of the iris in the region of the CC entry and the 133 
inner corneoscleral junction. The length of the CC noted (d) corresponded to the distance 134 
between the pectinate ligament (or the most anterior visible portion of the uveal trabecular 135 
meshwork) and the anterior part of the ciliary body. The width of the CC entry, marked (b) was 136 
the distance between the corneoscleral limbus and the iris root. The width of the mid-CC (c) 137 
was the distance between the inner sclera and the ciliary process in the central portion of the 138 
CC. The anterior chamber depth (e) was determined as the distance between the corneal 139 
endothelium in the apical region of the cornea and the anterior pole of the lens. The thickness 140 
of the cornea at the limbus (f) was the measure between the epithelium of the cornea and the 141 
endothelium in its most peripheral transparent part. The distance between the anterior capsule 142 
of the lens and the Schwalbe’s line (g) was described by Kawata and Hasegawa., 2013. The 143 
area of the ciliary cleft (h) was calculated by the area formula (CC) = (d / 2 x (b + c) / 2) + 144 
((cxd) / 4). All these measurements were performed by the UBM software caliper. 145 
5. Statistical evaluation 146 
 7 
For this study, 45 cats were divided into 3 homogeneous groups (weight, racial type, sex, age) 147 
of 15 individuals. Sample size n = 15 was determined using Student's t-test. Only five breeds 148 
of cats with a majority of European cats was represented in the three groups, the distribution 149 
was made in such a way as to obtain ages between 1 year and 10 years, an average weight of 150 
4.1 kg and a male / female ratio close to 50% (Table I). Each animal was submitted to only one 151 
experiment (one type of eye drops) and two general anesthesia 7 days apart. The 1440 data 152 
obtained, including measurements of IOP and anterior segment biometry on the left (untreated) 153 
and right (treated) eyes, on D0 and D7 were integrated into a statistical model, in which the 154 
experimental unit was a cat, and the variable factor was the type of eyedrops instilled for 7 days. 155 
The objective of the statistical study was to determine the effects of these three molecules on 156 
anterior segment biometry and IOP. For this, two statistical methods were used: the non-157 
parametric Wilcoxon test to evaluate the significant or non-significant differences between two 158 
independent groups and a one-way analysis of variance (ANOVA) to compare the sample 159 
means. The level of significance was set at p<.05 for all statistical analyses.  160 
 161 
Results 162 
 163 
The IOP and biometric measurements of the anterior segment of the untreated eye (left eye) did 164 
not significantly differ between D0 and D7. And no significant difference in the biometric data 165 
of the anterior segment was found on day 0 between the untreated eye and the treated eye. After 166 
one week of instillation of dorzolamide 2%, the IOP of the treated eye was significantly 1mmHg 167 
lower (Figure 3). This decrease was relatively moderate (5.3%). After one week of instillation 168 
of latanosprost or timolol, the IOP of the treated eye did not significantly decrease (Figure 3). 169 
About biometric data, ICA values (a), the width of the entrance of the CC (b), the width of the 170 
mid-CC (c), the length of the CC (d), the anterior chamber depth (e), the distance between the 171 
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anterior capsule of the lens and the Schwalbe’s line (g) and the area of the ciliary cleft (h) were 172 
not significantly altered after 7 days of instillation whatever the eye drops. Only a significant 173 
decrease of 1.4% in corneal thickness (f) was observed with the instillation of dorzolamide 174 
(Figure 4), whereas there was a significant increase of 1.6% in thickness of the cornea (f) with 175 
the instillation of timolol (Figure 4). 176 
 177 
Discussion 178 
 179 
In this study, the parameters measured on the untreated eye (IOP and biometric data) did not 180 
vary between D0 and D7. It was therefore admitted that eye drops instilled on the treated eye 181 
(OD) for 7 days had no significant effect on the parameters measured on the untreated eye (OS) 182 
and this despite a possible systemic diffusion of eye drops. In addition, the absence of a 183 
significant difference in the data measured between the treated (OD) and untreated (OS) eye on 184 
D0 allowed to validate the use of the untreated eye (OS) as a control at D0 and D7. The study 185 
could also have been performed by comparing the data of the treated eye (OD) to D0 and D7. 186 
Both analyses were performed with the same statistical tests and we observed the same 187 
variations. 188 
In contrast with healthy dogs for which these three types of hypotensive agents cause a 189 
significant decrease in IOP [Poinsard et al., 2018], only instillation of dorzolamide at 2% twice 190 
daily for 7 days resulted in a moderate but significant decrease in IOP in healthy cats in this 191 
study. This result is similar to previous studies evaluating the effects of 2% dorzolamide 192 
instilled in the eyes of healthy cats [Rainbow and Dziezyc, 2003], [Dietrich et al., 2007] and 193 
[Rankin et al., 2012]. This moderate decrease in IOP of 1 mmHg (5.5%) is close to the decrease 194 
(1.6 mmHg) in the Dietrich study (2007) when 2% dorzolamide is instilled twice daily. 195 
Increasing the frequency of instillation of dorzolamide 2% to 3 times daily does not appear to 196 
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significantly increase the hypotensive effect of dorzolamide in healthy cats [Dietrich et al., 197 
2007]. This modest effect of topical carbonic anhydrase inhibitors on the feline eye is also 198 
viewed in an earlier study of 20 healthy cats, where IOP did not significantly decrease after 199 
instillation of 1% brinzolamide for 7 days, twice a day [Gray and al., 2003]. This moderate 200 
response in healthy cats does not question the interest of dorzolamide in the medical 201 
management of glaucoma in cats, since the Sigle study in 2011 [Sigle and al., 2011] reveals an 202 
interesting decrease in IOP of 7 cats with primary congenital glaucoma with dorzolamide 203 
instilled 3 times a day. 204 
The instillation twice daily of timolol for 7 days on the eyes of healthy cats did not lead to a 205 
significant reduction in IOP between day 0 and day 7 in this study. This result is similar to that 206 
obtained in the Kiland study [Kiland and al., 2016] and contrary to the older studies of Wilkie 207 
and Latimer in 1991 and Colasanti and Trotter in 1981. In the Dietrich study (2007), 208 
concomitant administration of dorzolamide and timolol did not have a more intense hypotensive 209 
effect than dorzolamide alone. 210 
Finally, instillation of latanoprost once daily for 7 days in healthy cats’ eyes did not decrease 211 
the IOP between day 0 and day 7 in this study, which is consistent with previous studies on the 212 
effects of latanoprost on the IOP of healthy cats [Mc Donald and al., 2016], [Studer and al., 213 
2000]. This lack of efficacy of PGF2 alpha receptor analogs is attributed to species differences 214 
in prostaglandin receptors in the ciliary bodies of the cat's eye that express EP and DP receptors 215 
rather than FP receptors, found in particular in humans [Regnier and al., 2006]. 216 
The absence of significant modification of the anterior segment biometry in this study during 217 
instillation of timolol and latanoprost in healthy cats confirms the lack of response of these 218 
molecules to IOP after 7 days of treatment.  219 
Regarding dorzolamide 2%, the absence of significant modification on the biometry of the 220 
anterior segment confirms that dorzolamide acts on the IOP by lowering the production of HA 221 
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without interacting on the outflow pathway of HA. The lack of effect on AIC biometrics of 222 
these three molecules in healthy cats is similar to the results obtained in healthy dogs using the 223 
same protocol and the same operator [Poinsard and al., 2018]. A decrease of 1.4% in the 224 
thickness of the peripheral cornea in cats treated with dorzolamide was found, this decrease 225 
similar to treated dogs [Poinsard and al., 2018] can be related to a transient dehydration of the 226 
cornea. Conversely, a 1.6% increase in the thickness of the peripheral cornea in cats treated 227 
with timolol was noted: this can be related to a transient edema of the cornea. 228 
Differences in IOP results with some studies during instillation of timolol may be related to the 229 
type of tonometer used. Nevertheless, Tonovet® provides accurate and reproducible IOP 230 
measurements in cats [McLellan and al., 2013]. Although all the qualitative measurements on 231 
the anterior chamber angle and sclerociliary cleft are perfectly described by Dulaurent et al., 232 
2012, the precision of the UBM measurements remains a variable dependent on the experience 233 
of the operator. It is important to remember that the comparison of the data between healthy 234 
dogs and healthy cats is reinforced by the fact that these two studies were carried out by the 235 
same operator and under the same conditions. 236 
This study has the same limitations as the study by Poinsard et al., 2018, limitations related to 237 
the recruitment mode (private structure) causing a double selection bias, especially for breeds 238 
that may have specificities, and the number of cats presented. Even if these three molecules 239 
showed little or no influence on IOP and anterior segment biometry in healthy cats, it would be 240 
interesting to carry out the same study in a context of glaucomatous cats. 241 
 242 
Conclusion 243 
This prospective study revealed a significant decrease in IOP in healthy cats treated with 244 
dorzolamide at 2% BID for 7 days. Timolol 1% BID and latanoprost SID have no effect on IOP 245 
after 7 days of treatment in healthy cats. Finally, dorzolamide 2%, timolol 0.5% and latanoprost 246 
 11 
0.005% have no effect on the biometry of AIC in healthy cats with the protocol used and the 247 
duration studied. 248 
 249 
 250 
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Iconography 326 
 327 
Figure 1: Utrasound biomicroscopy (UBM) of the iridocorneal angle and ciliary cleft in a 328 
normal cat. 329 
 330 
Figure 2: Histological aspect of the anterior segment of a dog's eye showing the main biometric 331 
parameters studied in cats. 332 
 333 
Table I: Summary of race, age, gender and weight data for cats in the cohort.  334 
 335 
Figure 3: Box chart of IOP variations after one week of anti-glaucoma therapy on the treated 336 
eye (DOR: dorzolamide 2%, TI: timolol 0.5%, LAN: latanoprost 0.005%). 337 
 338 
Figure 4: Box chart of corneal thickness variations (f) after one week of anti-glaucoma 339 
treatment on the treated eye. 340 
 341 
Table II: Mean value of the IOP (mmHg) after one week of anti-glaucoma treatment on the 342 
treated eye. 343 
 344 
Table III: Mean value of the corneal thickness (f) (mm) after one week of anti-glaucoma 345 
treatment on the treated eye. 346 
 347 
Table IV: Mean value of the width of the entrance of the ciliary cleft (b) (mm) after one week 348 
of anti-glaucoma treatment on the treated eye. 349 
  350 
 351 
 352 
 353 
Table I: Summary of race, age, gender, and weight data for cats in the cohort 354 
 355 
Group 1 Group 2 Group 3 
Breed  Age Gender 
  
Weight Breed  Age 
 
Gender 
   
Weight Breed  Age Gender 
     
Weight 
European 5 Mn 4 European 
  
8 Fn 5 European 1 Mn 4 
European 2 Fn 4 European 1 Mn 3 European 
  
1 Fn 3 
European      8  Mn 5  European  1  Mn  3  Persian 
  
1 M 4 
European 1 Fn 4 European 6  Fn 5 European 
  
7 Mn 5 
European 
  
1 Fn 6 European  1  Mn  3  European  6 Fn 6  
Persian 2 Mn 3 European 8 Mn 6 European 9 Fn 5  
 15 
  
European 
  
1     F 3 Oriental 
shorthair  
1  Mn  3  European 4 Mn 6  
European 
  
4 Mn 4 European 2 Fn 4 European  4 Mn 4  
European 
  
6 Mn 4 European 6 Fn 5 European 6 Fn 4 
European 
  
1 Mn 6 European  10 Mn 5 European  1 Mn 3  
European 
  
8 Fn 3 European 8    Fn 3 European 4 Fn 4 
European 
  
9 Mn 6 European 3 Mn 4 European 2 Mn 3 
European 
  
6 Fn 3 European 3 Fn 4 European 8 Mn 5 
Somali 4 F 2 Abyssin  2 Fn 3 European 
  
4 Mn 4  
European 10 Fn 5 European 1 Fn 3 Somali 1 Fn 3 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
Table II: Mean value of the IOP (mmHg) after one week of anti-glaucoma treatment on the 365 
treated eye. 366 
 367 
 Dorzolamide 2% Timolol 0,5% Latanoprost 0,005% 
PIO Mean D0 (mmHg) 17,6 16,8 18,3 
PIO Mean D7 (mmHg) 16,6 17 18,6 
 368 
 369 
 370 
 371 
 372 
 373 
 16 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
 390 
Table III: Mean value of the corneal thickness (f) (mm) after one week of anti-glaucoma 391 
treatment on the treated eye. 392 
 393 
 Dorzolamide 2% Timolol 0,5% Latanoprost 0,005% 
(f) Mean D0 (mm) 0,64 0,63 0,64 
(f) Mean D7 (mm) 0,63 0,64 0,64 
 394 
 395 
 396 
 397 
 398 
 17 
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Table IV: Mean value of the width of the entrance of the ciliary cleft (b) (mm) after one week 418 
of anti-glaucoma treatment on the treated eye. 419 
 420 
 Dorzolamide 2% Timolol 0,5% Latanoprost 0,005% 
(b) Mean D0 (mm) 0,82 0,80 0,85 
(b) Mean  D7 (mm) 0,84 0,8 0,86 
 421 
